Most patients using weight-loss drugs like Wegovy stop within a year, data show 


Reuters exclusively reported that Only about one-third of patients prescribed a popular weight-loss drug like Novo Nordisk’s (NOVOb.CO) Wegovy were still taking it a year later, while total healthcare costs for the group rose sharply.

Market Impact

Shares of the Danish drugmaker fell 2.3% on Tuesday.

Article Tags

Topics of Interest: Health

Type: Reuters Best

Sectors: Pharmaceuticals & Healthcare

Regions: Americas

Countries: United States

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Significant National Story

Source link

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart